These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

425 related items for PubMed ID: 8558199

  • 1. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group.
    Kobayashi T, Miyawaki S, Tanimoto M, Kuriyama K, Murakami H, Yoshida M, Minami S, Minato K, Tsubaki K, Ohmoto E, Oh H, Jinnai I, Sakamaki H, Hiraoka A, Kanamaru A, Takahashi I, Saito K, Naoe T, Yamada O, Asou N, Kageyama S, Emi N, Matsuoka A, Tomonaga M, Ohno R.
    J Clin Oncol; 1996 Jan; 14(1):204-13. PubMed ID: 8558199
    [Abstract] [Full Text] [Related]

  • 2. Randomized study of individualized induction therapy with or without VCR, and of maintenance of 4 or 12 courses in adult AML: JALSG-AML87. Japan Adult Leukemia Study Group (JALSG).
    Ohno R, Kobayashi T, Morishima Y, Hiraoka A, Imai K, Asoh N, Tsubaki K, Tomonaga M, Takahashi I, Kodera K.
    Leukemia; 1992 Jan; 6 Suppl 2():92-5. PubMed ID: 1578954
    [Abstract] [Full Text] [Related]

  • 3. No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group.
    Miyawaki S, Tanimoto M, Kobayashi T, Minami S, Tamura J, Omoto E, Kuriyama K, Hatake K, Saito K, Kanamaru A, Oh H, Ohtake S, Asou N, Sakamaki H, Yamada O, Jinnai I, Tsubaki K, Takeyama K, Hiraoka A, Matsuda S, Takahashi M, Shimazaki C, Adachi K, Kageyama S, Ohno R.
    Int J Hematol; 1999 Aug; 70(2):97-104. PubMed ID: 10497848
    [Abstract] [Full Text] [Related]

  • 4. Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group.
    Ohno R, Kobayashi T, Tanimoto M, Hiraoka A, Imai K, Asou N, Tomonaga M, Tsubaki K, Takahashi I, Kodera Y.
    Cancer; 1993 Jun 15; 71(12):3888-95. PubMed ID: 8508355
    [Abstract] [Full Text] [Related]

  • 5. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group.
    Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, Omoto E, Akiyama H, Tsubaki K, Saito K, Kuriyama K, Oh H, Kitano K, Miyawaki S, Takeyama K, Yamada O, Nishikawa K, Takahashi M, Matsuda S, Ohtake S, Suzushima H, Emi N, Ohno R.
    J Clin Oncol; 1998 Jan 15; 16(1):78-85. PubMed ID: 9440726
    [Abstract] [Full Text] [Related]

  • 6. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R, Japan Adult Leukemia Study Group AML 97 Study.
    Cancer; 2005 Dec 15; 104(12):2726-34. PubMed ID: 16284985
    [Abstract] [Full Text] [Related]

  • 7. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
    Löwenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R, Dekker AW, Berneman ZN, Thyss A, van der Lelie J, Sonneveld P, Visani G, Fillet G, Hayat M, Hagemeijer A, Solbu G, Zittoun R.
    J Clin Oncol; 1998 Mar 15; 16(3):872-81. PubMed ID: 9508168
    [Abstract] [Full Text] [Related]

  • 8. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group.
    Kanamaru A, Takemoto Y, Tanimoto M, Murakami H, Asou N, Kobayashi T, Kuriyama K, Ohmoto E, Sakamaki H, Tsubaki K.
    Blood; 1995 Mar 01; 85(5):1202-6. PubMed ID: 7858250
    [Abstract] [Full Text] [Related]

  • 9. [Effect of etoposide added to individualized induction therapy of adult acute myeloid leukemia--the JALSG-AML-92 Study. Japan Adult Leukemia Study Group].
    Miyawaki S, Tanimoto M, Kobayashi T, Minami S, Tamura J, Omoto E, Kuriyama K, Hatake K, Saito K, Ohno R.
    Gan To Kagaku Ryoho; 2000 Jul 01; 27(8):1160-7. PubMed ID: 10945011
    [Abstract] [Full Text] [Related]

  • 10. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.
    Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, Bickers JN, Hynes HE, Welborn JL, Simon SR, Grever M.
    Blood; 1996 Oct 15; 88(8):2841-51. PubMed ID: 8874180
    [Abstract] [Full Text] [Related]

  • 11. Repeated cycles of G-CSF-combined postremission chemotherapy for acute myeloid leukemia in a first complete remission: a pilot study.
    Ogata K, An E, Kamikubo K, Yokose N, Tamura H, Yamada T, Gomi S, Dan K, Nomura T.
    Stem Cells; 1998 Oct 15; 16(4):280-7. PubMed ID: 9708450
    [Abstract] [Full Text] [Related]

  • 12. All-trans retinoic acid therapy for newly diagnosed acute promyelocytic leukemia: comparison with intensive chemotherapy. The Japan Adult Leukemia Study Group (JALSG).
    Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, Omoto E, Sakamaki H, Tsubaki K, Saito K, Ohno R.
    Cancer Chemother Pharmacol; 1997 Oct 15; 40 Suppl():S30-5. PubMed ID: 9272131
    [Abstract] [Full Text] [Related]

  • 13. Intensive individualized induction therapy with behenoyl cytarabine, daunorubicin and 6-mercaptopurine followed by intensive consolidation including intermediate-dose continuous cytarabine, mitoxantron, etoposide and vinca alkaloids in acute myeloid leukemia in adults.
    Ohno R, Yokomaku S, Okumura M, Nagai T, Kitaori K, Ito T, Takeo T, Sugiura I, Yano K, Ito Y.
    Int J Hematol; 1991 Dec 15; 54(6):487-93. PubMed ID: 1793832
    [Abstract] [Full Text] [Related]

  • 14. Maintenance therapy in childhood acute myeloid leukemia.
    Perel Y, Auvrignon A, Leblanc T, Michel G, Vannier JP, Dalle JH, Gandemer V, Schmitt C, Mèchinaud F, Lamagnere JP, Piguet Ch, Couillaud G, Pautard B, Baruchel A, Leverger G, Group LAME, French Society of Pediatric Hematology and Immunology.
    Ann Hematol; 2004 Dec 15; 83 Suppl 1():S116-9. PubMed ID: 15124700
    [Abstract] [Full Text] [Related]

  • 15. Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length.
    Ohno R, Kato Y, Nagura E, Murase T, Okumura M, Yamada H, Ogura M, Minami S, Suzuki H, Morishima Y.
    J Clin Oncol; 1986 Dec 15; 4(12):1740-7. PubMed ID: 3465875
    [Abstract] [Full Text] [Related]

  • 16. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
    Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ.
    Cancer Res; 1998 Sep 15; 58(18):4173-9. PubMed ID: 9751631
    [Abstract] [Full Text] [Related]

  • 17. [A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute].
    Fujiwara M, Satou N, Izumi N, Shibasaki Y, Higashimura M, Tsukada N, Koike T.
    Gan To Kagaku Ryoho; 2007 Nov 15; 34(11):1793-8. PubMed ID: 18030012
    [Abstract] [Full Text] [Related]

  • 18. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia.
    Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, Cobcroft R, Herrmann R, Van Der Weyden M, Lowenthal RM, Page F, Garson OM, Juneja S.
    Blood; 1996 Mar 01; 87(5):1710-7. PubMed ID: 8634416
    [Abstract] [Full Text] [Related]

  • 19. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
    Fukushima T, Urasaki Y, Yamaguchi M, Ueda M, Morinaga K, Haba T, Sugiyama T, Nakao S, Origasa H, Umehara H, Ueda T.
    Anticancer Res; 2012 Feb 01; 32(2):643-7. PubMed ID: 22287757
    [Abstract] [Full Text] [Related]

  • 20. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
    Farag SS, Ruppert AS, Mrózek K, Mayer RJ, Stone RM, Carroll AJ, Powell BL, Moore JO, Pettenati MJ, Koduru PR, Stamberg J, Baer MR, Block AW, Vardiman JW, Kolitz JE, Schiffer CA, Larson RA, Bloomfield CD.
    J Clin Oncol; 2005 Jan 20; 23(3):482-93. PubMed ID: 15534356
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.